Algorae Pharmaceuticals Limited (ASX:1AI) has disclosed a change in the relevant interests of director David Hainsworth, following an on-market purchase of 2,062,500 fully paid ordinary shares on 17 November 2026 through his indirectly held entity Cathedral Estate Pty Ltd, trading as the Cathedral Super Fund.

Key Points

  • Director David Hainsworth acquired 2,062,500 fully paid ordinary shares on 17 November 2026 at a consideration of $18,562.50 via an on-market trade.
  • The shares were acquired indirectly through Cathedral Estate Pty Ltd <Cathedral Super Fund>, an entity in which Mr Hainsworth is a director and controlling shareholder.
  • Following the transaction, Cathedral Estate Pty Ltd holds 8,000,000 fully paid ordinary shares, up from 5,937,500 prior to the change.
  • No securities were disposed of as part of this transaction, and no changes were recorded in director interests in contracts.

Transaction Details and Consideration

According to the filing, the acquisition of 2,062,500 fully paid ordinary shares was conducted as an on-market trade on 17 November 2026. The total consideration paid was $18,562.50. The transaction was executed through Cathedral Estate Pty Ltd, operating under the Cathedral Super Fund account, an entity in which Mr Hainsworth holds the roles of director and controlling shareholder. The filing confirms that no securities were disposed of in connection with this transaction, and the change did not occur during a closed period requiring prior written clearance.

Director's Full Securities Holdings After Change

Following the transaction, Mr Hainsworth's total holdings span direct and indirect interests. His direct holdings remain unchanged at 20,000,000 fully paid ordinary shares, 20,000,000 performance rights from the AGM 2024, 30,000,000 performance rights from the AGM 2025, and 4,000,000 unlisted options with an exercise price of $0.014 expiring 1 December 2029. Through Union Square Capital Pty Ltd, Mr Hainsworth retains 30,000,000 performance rights from the AGM 2026. Through Cathedral Estate Pty Ltd, he now holds 8,000,000 fully paid ordinary shares and 1,125,000 unlisted options with an exercise price of $0.014 expiring 1 December 2029.

Prior Holdings and Indirect Interest Structure

Prior to the change disclosed on 17 November 2026, Cathedral Estate Pty Ltd held 5,937,500 fully paid ordinary shares and 1,125,000 unlisted options with an exercise price of $0.014 expiring 1 December 2029. The filing identifies two indirect interest vehicles for Mr Hainsworth: Union Square Capital Pty Ltd, operating under the Endeavor account, and Cathedral Estate Pty Ltd, operating under the Cathedral Super Fund account. The date of the last director's interest notice for Mr Hainsworth was recorded as 11 November 2026, with the current notice reflecting the subsequent on-market share acquisition.